샘플 요청 목록

 카트 문의
시장보고서
상품코드
1795154

세계의 지연성 운동장애 치료제 시장

Tardive Dyskinesia Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 240 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

지연성 운동장애 치료제 세계 시장은 2030년까지 56억 달러에 달할 전망

2024년에 43억 달러로 추정되는 지연성 운동장애 치료제 세계 시장은 분석 기간인 2024-2030년에 CAGR 4.4%로 성장하여 2030년에는 56억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 듀테트라베나진 의약품은 CAGR 5.0%를 기록하며 분석 기간 종료시에는 33억 달러에 달할 것으로 예측됩니다. 발베나진 의약품 부문의 성장률은 분석 기간 동안 CAGR 3.9%로 추정됩니다.

미국 시장은 11억 달러로 추정, 중국은 CAGR 4.3%로 성장 예측

미국의 지연성 운동장애 치료제 시장은 2024년에 11억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 9억 210만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 4.3%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 4.2%와 3.8%로 예측됩니다. 유럽에서는 독일이 CAGR 3.6%로 성장할 것으로 예측됩니다.

세계의 지연성 운동장애 치료제 시장 - 주요 동향과 촉진요인 정리

지연성 운동이상증(TD)은 항정신병약물의 장기 복용으로 인한 운동장애로, 전용 치료제에 대한 관심이 높아지고 있습니다.

기존 치료는 VMAT2 억제제에 의존하고 있으며, 임상적 검증 결과 VMAT2 억제제가 표준 치료제로 등장했습니다. 이러한 약물들은 증상 조절과 복용 편의성을 향상시켰지만, 신규 치료제 파이프라인은 여전히 제약이 있어 차세대 치료제의 필요성이 강조되고 있습니다. 고소득 지역은 탄탄한 의료 인프라와 항정신병 약물의 광범위한 사용으로 인해 채택률이 높지만, 신흥 시장은 인지도와 접근성이 높아지면서 관심이 가속화되고 있습니다. 약리학적 치료뿐만 아니라 다양한 치료법의 혁신이 치료를 확대하고 있습니다. 경구 투여가 여전히 일반적이지만, 증상이 심하거나 관리가 미흡한 환자에게는 주사제가 각광을 받고 있습니다. 치료법이 성숙함에 따라 조기 진단, 모니터링 도구, 행동 치료 및 지지적 개입을 포함한 통합적 접근법에도 관심이 집중되고 있습니다.

약물 치료 이외의 치료법은 어떻게 발전하고 있는가?

뇌심부자극요법, 경두개 자기자극요법 등 비약물 요법은 인프라 및 비용 문제로 아직 보편화되지는 않았지만, 관심을 받고 있습니다. 서방형 제제 및 개별화된 투여 스케줄의 기술적 개선으로 환자들의 치료 성과가 향상되고 있습니다. 그 결과, adherence와 QOL이 중심적인 평가 지표가 되고 있습니다.

실제 데이터 이니셔티브는 장기적인 결과를 추적하는 데 도움이 되며, 환자 경험과 순응도에 대한 인사이트를 제공합니다. 이러한 데이터베이스는 규제 기관과 의료 서비스 제공자에게 치료 효과, 안전성, 경제성에 대한 정보를 제공하여 보다 정교한 치료 알고리즘과 가치 기반 치료 전략으로 나아갈 수 있는 길을 열어주고 있습니다.

지연성 운동 이상증 치료제 시장의 성장은 몇 가지 요인에 의해 초래됩니다...

TD 치료제 시장의 성장은 진단의 고도화, 치료의 다양화, 환자 인식 개선과 관련된 여러 요인에 의해 주도되고 있습니다. 전 세계적으로 TD의 유병률이 증가함에 따라 잠재적 환자층이 확대되고 있습니다. 진단의 발전과 임상적 인식의 향상으로 조기 개입이 가능해졌습니다. 정밀의료로의 전환은 비약리학적 옵션을 포함한 맞춤형 치료 접근법에 대한 관심을 불러일으키고 있습니다. 또한, 환자 등록 및 결과 추적은 현실 세계에서 의사결정과 치료 접근성을 개선하고 있습니다. 이러한 복합적인 힘에 의해 보다 신속하고 확장 가능한 TD 치료의 전망이 형성되고 있습니다.

부문

약제(듀테트라베나진 제제, 발베나진 제제, 기타 약제), 제품(지연성 운동장애 고형제, 지연성 운동장애 정제, 지연성 운동장애 캡슐, 지연성 운동장애 액제, 지연성 운동장애 주사제), 판매 채널(병원 약국, 드럭스토어·소매 약국, 온라인 판매 채널, 기타 판매 채널)

조사 대상 기업 사례

  • AbbVie Inc.
  • Adamas Pharmaceuticals, Inc.
  • Addex Therapeutics Ltd.
  • Amneal Pharmaceuticals, Inc.
  • Biogen Inc.
  • Chromium Therapeutics(add pipeline)*
  • Contera Pharma
  • Dr. Reddy's Laboratories
  • Johnson & Johnson
  • Lundbeck A/S
  • Mitsubishi Tanabe Pharma Corporation
  • Neurocrine Biosciences, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanis
  • SOM Biotech
  • SteriMax Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계 고유의 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

KSM 25.08.29

Global Tardive Dyskinesia Therapeutics Market to Reach US$5.6 Billion by 2030

The global market for Tardive Dyskinesia Therapeutics estimated at US$4.3 Billion in the year 2024, is expected to reach US$5.6 Billion by 2030, growing at a CAGR of 4.4% over the analysis period 2024-2030. Deutetrabenazine Drug, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$3.3 Billion by the end of the analysis period. Growth in the Valbenazine Drug segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 4.3% CAGR

The Tardive Dyskinesia Therapeutics market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$902.1 Million by the year 2030 trailing a CAGR of 4.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 3.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Tardive Dyskinesia Therapeutics Market - Key Trends & Drivers Summarized

Tardive dyskinesia (TD), a movement disorder stemming from prolonged antipsychotic use, has catalyzed a growing focus on dedicated therapeutics.

Traditional management relied heavily on VMAT2 inhibitors, which have emerged as standard treatments following clinical validation. While these drugs improved symptom control and dosing convenience, the pipeline for novel therapies remains constrained, emphasizing the need for next-gen interventions. High-income regions lead adoption due to robust healthcare infrastructure and widespread antipsychotic use, while emerging markets are showing accelerated interest as awareness and access improve. Beyond pharmacological treatment, a range of delivery innovations is expanding care. Oral administration remains common, but injectables are gaining momentum for patients with severe or poorly managed symptoms. As therapies mature, attention is also turning toward early diagnosis, monitoring tools, and integrative approaches that include behavioral and supportive interventions.

How Are Treatment Modalities Evolving Beyond Medication?

Non-drug interventions such as deep brain stimulation and transcranial magnetic stimulation are gaining interest, though they remain less common due to infrastructure and cost. Technological improvements in extended-release drug formulations and individualized dosing schedules are enhancing patient outcomes. As a result, adherence and quality of life are becoming central performance metrics.

Real-world data initiatives are helping track long-term outcomes, offering insights into patient experience and adherence. These databases inform regulatory bodies and healthcare providers on therapeutic effectiveness, safety, and economic viability, paving the way for more nuanced treatment algorithms and value-based care strategies.

The Growth in the Tardive Dyskinesia Therapeutics Market Is Driven by Several Factors…

The growth in the TD therapeutics market is driven by several factors related to diagnostic sophistication, treatment diversification, and increasing patient recognition. Rising global prevalence of TD is expanding the potential patient base. Advancements in diagnostics and heightened clinical awareness are enabling earlier intervention. The shift toward precision medicine is prompting interest in personalized treatment approaches, including non-pharmacologic options. Additionally, patient registries and outcome tracking are improving real-world decision-making and access to care. These combined forces are shaping a more responsive and scalable TD therapeutic landscape.

SCOPE OF STUDY:

The report analyzes the Tardive Dyskinesia Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug (Deutetrabenazine Drug, Valbenazine Drug, Other Drugs); Product (Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form, Tardive Dyskinesia Injection); Distribution Channel (Hospitals Pharmacies, Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 48 Featured) -

  • AbbVie Inc.
  • Adamas Pharmaceuticals, Inc.
  • Addex Therapeutics Ltd.
  • Amneal Pharmaceuticals, Inc.
  • Biogen Inc.
  • Chromium Therapeutics (add pipeline)*
  • Contera Pharma
  • Dr. Reddy's Laboratories
  • Johnson & Johnson
  • Lundbeck A/S
  • Mitsubishi Tanabe Pharma Corporation
  • Neurocrine Biosciences, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanis
  • SOM Biotech
  • SteriMax Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Tardive Dyskinesia Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Diagnosis Rates of Tardive Dyskinesia Due to Improved Clinical Awareness Drive Therapeutic Demand
    • Increased Use of Antipsychotics and Dopamine Receptor Blockers Spurs Incidence of TD
    • Development of VMAT2 Inhibitors Propels Market for Targeted Tardive Dyskinesia Treatments
    • Expansion of Mental Health Services Enhances Access to Early Intervention and Diagnosis
    • Clinical Evidence Supporting Long-Term Efficacy of New Drug Classes Strengthens Physician Adoption
    • Shift Toward Neurologist-Led Management Models Promotes Use of Specialized Therapies
    • Growing Demand for Patient-Centric and Side Effect-Minimized Regimens Supports Treatment Customization
    • FDA Approvals and Label Expansions Fuel Uptake of Novel Small Molecule Therapies
    • Rise in Co-Occurrence With Other Psychiatric Disorders Increases Demand for Combination Therapies
    • Inclusion of TD Therapies in Psychiatric Formularies Boosts Institutional Access
    • Development of Long-Acting Formulations Improves Adherence and Quality of Life Outcomes
    • Monitoring Protocols and Tolerability Data Collection Shape Prescribing Trends in Community Practices
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Tardive Dyskinesia Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Tardive Dyskinesia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Tardive Dyskinesia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Deutetrabenazine Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Deutetrabenazine Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Deutetrabenazine Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Valbenazine Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Valbenazine Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Valbenazine Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Drug Stores & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospitals Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Tardive Dyskinesia Solid Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Tardive Dyskinesia Solid Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Tardive Dyskinesia Solid Dosage Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Tardive Dyskinesia Tablets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Tardive Dyskinesia Tablets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Tardive Dyskinesia Tablets by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Tardive Dyskinesia Capsules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Tardive Dyskinesia Capsules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Tardive Dyskinesia Capsules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Tardive Dyskinesia Liquid Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Tardive Dyskinesia Liquid Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Tardive Dyskinesia Liquid Dosage Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Tardive Dyskinesia Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Tardive Dyskinesia Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Tardive Dyskinesia Injection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Tardive Dyskinesia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Tardive Dyskinesia Therapeutics by Drug - Percentage Breakdown of Value Sales for Deutetrabenazine Drug, Valbenazine Drug and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Tardive Dyskinesia Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Tardive Dyskinesia Therapeutics by Product - Percentage Breakdown of Value Sales for Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Tardive Dyskinesia Therapeutics by Drug - Percentage Breakdown of Value Sales for Deutetrabenazine Drug, Valbenazine Drug and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Tardive Dyskinesia Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Tardive Dyskinesia Therapeutics by Product - Percentage Breakdown of Value Sales for Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection for the Years 2014, 2025 & 2030
  • JAPAN
    • Tardive Dyskinesia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Tardive Dyskinesia Therapeutics by Drug - Percentage Breakdown of Value Sales for Deutetrabenazine Drug, Valbenazine Drug and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Tardive Dyskinesia Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Tardive Dyskinesia Therapeutics by Product - Percentage Breakdown of Value Sales for Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection for the Years 2014, 2025 & 2030
  • CHINA
    • Tardive Dyskinesia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Tardive Dyskinesia Therapeutics by Drug - Percentage Breakdown of Value Sales for Deutetrabenazine Drug, Valbenazine Drug and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Tardive Dyskinesia Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: China 16-Year Perspective for Tardive Dyskinesia Therapeutics by Product - Percentage Breakdown of Value Sales for Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection for the Years 2014, 2025 & 2030
  • EUROPE
    • Tardive Dyskinesia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Tardive Dyskinesia Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Tardive Dyskinesia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Tardive Dyskinesia Therapeutics by Drug - Percentage Breakdown of Value Sales for Deutetrabenazine Drug, Valbenazine Drug and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Tardive Dyskinesia Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Tardive Dyskinesia Therapeutics by Product - Percentage Breakdown of Value Sales for Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection for the Years 2014, 2025 & 2030
  • FRANCE
    • Tardive Dyskinesia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Tardive Dyskinesia Therapeutics by Drug - Percentage Breakdown of Value Sales for Deutetrabenazine Drug, Valbenazine Drug and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Tardive Dyskinesia Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: France 16-Year Perspective for Tardive Dyskinesia Therapeutics by Product - Percentage Breakdown of Value Sales for Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection for the Years 2014, 2025 & 2030
  • GERMANY
    • Tardive Dyskinesia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Tardive Dyskinesia Therapeutics by Drug - Percentage Breakdown of Value Sales for Deutetrabenazine Drug, Valbenazine Drug and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Tardive Dyskinesia Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Tardive Dyskinesia Therapeutics by Product - Percentage Breakdown of Value Sales for Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Tardive Dyskinesia Therapeutics by Drug - Percentage Breakdown of Value Sales for Deutetrabenazine Drug, Valbenazine Drug and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Tardive Dyskinesia Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Tardive Dyskinesia Therapeutics by Product - Percentage Breakdown of Value Sales for Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Tardive Dyskinesia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Tardive Dyskinesia Therapeutics by Drug - Percentage Breakdown of Value Sales for Deutetrabenazine Drug, Valbenazine Drug and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Tardive Dyskinesia Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Tardive Dyskinesia Therapeutics by Product - Percentage Breakdown of Value Sales for Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Europe Historic Review for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Europe 16-Year Perspective for Tardive Dyskinesia Therapeutics by Drug - Percentage Breakdown of Value Sales for Deutetrabenazine Drug, Valbenazine Drug and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Europe 16-Year Perspective for Tardive Dyskinesia Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 16-Year Perspective for Tardive Dyskinesia Therapeutics by Product - Percentage Breakdown of Value Sales for Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Tardive Dyskinesia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Asia-Pacific Historic Review for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Asia-Pacific 16-Year Perspective for Tardive Dyskinesia Therapeutics by Drug - Percentage Breakdown of Value Sales for Deutetrabenazine Drug, Valbenazine Drug and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Asia-Pacific 16-Year Perspective for Tardive Dyskinesia Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 16-Year Perspective for Tardive Dyskinesia Therapeutics by Product - Percentage Breakdown of Value Sales for Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection for the Years 2014, 2025 & 2030
  • REST OF WORLD
    • TABLE 143: Rest of World Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of World Historic Review for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of World 16-Year Perspective for Tardive Dyskinesia Therapeutics by Drug - Percentage Breakdown of Value Sales for Deutetrabenazine Drug, Valbenazine Drug and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 146: Rest of World Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of World Historic Review for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of World 16-Year Perspective for Tardive Dyskinesia Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 149: Rest of World Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of World Historic Review for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Rest of World 16-Year Perspective for Tardive Dyskinesia Therapeutics by Product - Percentage Breakdown of Value Sales for Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제